Proactive Cancer Prediction Using IoT and Deep Learning Before Symptoms

Mohamed Amine Meddaoui, Imane Karkaba, Moulay Amzil, Mohammed Erritali
Data4Earth Laboratory, Sultan Moulay Slimane University, Beni Mellal, Morocco

***Abstract*—The ability to predict cancer before the onset of clinical symptoms represents a paradigm shift in oncology and preventive medicine. Existing diagnostic approaches remain reactive, relying on imaging or symptomatic manifestations that frequently detect the disease only at advanced stages, particularly in pancreatic, lung, and ovarian cancers. To address this gap, we propose a novel methodology that integrates the Internet of Things (IoT), Artificial Intelligence (AI), and Deep Learning for proactive cancer prediction. Continuous high-resolution physiological, behavioral, and environmental data are collected through IoT-enabled wearable and implantable devices and analyzed using a hybrid architecture that combines Autoencoders, Convolutional Neural Networks (CNNs), and Recurrent Neural Networks (RNNs), with a specific focus on Long Short-Term Memory (LSTM) models. Unlike previous work, which primarily targeted general IoT-based monitoring or symptom-driven detection, this study explicitly demonstrates how the fusion of multidimensional IoT data and advanced deep learning enables the identification of micro-level deviations from an individual's baseline as early biomarkers of cancer risk. Experiments conducted on synthetic datasets simulating pancreatic, lung, and ovarian cancer progression show that the proposed framework achieves an accuracy of 89%, a sensitivity of 85%, a specificity of 91%, and an AUC of 0.93, with an average early detection lead time of 7.5 months. These findings highlight the rigor and originality of the proposed approach, which advances the field by offering a validated, proactive methodology for cancer prediction and establishing clear differences from prior studies by the authors that focused on narrower IoT applications. This work paves the way for predictive and preventive oncology, where intervention can occur long before clinical manifestation of the disease.**

Keywords*—Deep learning; internet of things; artificial intelligence; convolutional neural network; recurrent neural network; long short-term memory; autoencoders; cancer prediction

I. Introduction

Cancer remains one of the most pressing global health challenges and a leading cause of mortality, accounting for nearly ten million deaths annually according to the World Health Organization. Despite significant advances in therapeutic protocols and diagnostic technologies, for Hussain [1], survival outcomes continue to depend heavily on the stage at which the disease is detected. The medical consensus is clear: early detection substantially improves survival rates as proposed by Moglia [2]. It reduces the invasiveness of treatment, and enhances patients' quality of life. Nevertheless, conventional diagnostic approaches such as imaging, biomarker assays, and population-wide screening, for Gong [3], these programs often identify cancer only after the appearance of macroscopic lesions or clinical symptoms. For aggressive cancers such as pancreatic, lung, and ovarian, symptoms usually manifest at advanced stages as cited by Bicheng [4], leaving patients with limited treatment options and poor prognosis. This reality underscores the inadequacy of the existing reactive paradigm in oncology, where interventions predominantly occur after disease manifestation. In recent years, there has been a shift toward preventive and predictive medicine, as tried by Panda [5], aiming to anticipate and mitigate disease before symptoms appear. Within oncology, the ability to forecast cancer, as proposed by Tirumanadham [6], risk in pre-symptomatic stages, represents a transformative opportunity. Such an approach would allow interventions long before tumor progression or metastasis, thereby opening the door to a truly preventive model of cancer care. For Yang [7], the emergence of the Internet of Things (IoT) and the rapid progress of Artificial Intelligence (AI), particularly deep learning, have created unique opportunities to realize this vision. IoT-enabled devices such as wearable sensors, implantable biosensors, and environmental monitoring systems can continuously capture multidimensional data streams reflecting physiological, behavioral, and environmental factors, for Meddaoui [8]. These data, imperceptible to conventional diagnostic methods, may reveal subtle deviations that precede clinical symptoms by several months. Deep learning models, with their capacity to handle complex and heterogeneous data, are ideally suited to detect such micro-level anomalies and temporal patterns, as mentioned by Anandan [9], enabling the proactive identification of elevated cancer risk. However, despite promising advances, existing research remains limited in scope. Most oncology studies rely on single modalities such as imaging or genomics, while IoT-based healthcare applications focus mainly on chronic disease management, patient monitoring, or symptom-driven detection. few, if any, frameworks integrate multimodal IoT data with advanced hybrid deep learning architectures for the specific purpose of pre-symptomatic cancer prediction. This gap highlights the need for a comprehensive, end-to-end methodology, as proposed by Zhang [10] that unifies continuous data collection with deep learning models capable of anomaly detection and temporal sequence analysis. The present work addresses this gap. The research problem examined in this study is the lack of integrated IoT–deep learning systems for proactive cancer prediction before the onset of clinical symptoms. As suggested by Youssef [11], the objective of this study is to design and evaluate a hybrid architecture that combines autoencoders, convolutional neural networks (CNNs), and recurrent neural networks (RNNs) with a specific focus on Long Short-Term Memory (LSTM), as presented by Zaher [12], models to detect subtle deviations from personalized health baselines. The key contributions of this study are fourfold: We

propose a novel proactive cancer prediction methodology that unifies continuous IoT-based data collection, as proposed by Savka [13], with a hybrid deep learning framework for anomaly detection and temporal modeling. We validate this methodology using simulated datasets for three cancers: pancreatic, as used by Mukherjee [14], lung and ovarian, where early detection remains particularly challenging. We introduce a new evaluation metric, the early detection lead time, as demonstrated by Islam [15], which quantifies the temporal advantage gained by identifying risks months before symptom onset. We clearly distinguish this work from our prior, as observed by Alatawi's [16] research on IoT-based monitoring applications by demonstrating its originality in targeting. For Parra [17], proactive oncology and establishing methodological innovations specific to cancer risk prediction.

The remainder of this study is structured as follows: Section II reviews the state-of-the-art in early cancer detection, IoT applications in healthcare, and deep learning in oncology. Section III presents the proposed methodology, including IoT-based data collection, preprocessing techniques, and the hybrid deep learning architecture. Section IV describes the experimental design, datasets, and results. Section V discusses clinical implications, limitations, and challenges, while Section VI concludes the study and outlines directions for future research in predictive and preventive oncology.

II. Related Work

The fight against cancer has always been at the heart of medical research, with considerable efforts dedicated to understanding its biology, like Soto [18], developing effective treatments, and improving detection strategies. Traditionally, for Mangayarkarasi [19], cancer detection relies on mass screening methods (mammography, cervical smear, colonoscopy) or on the investigation of clinical symptoms. For Meddaoui [20], although these approaches have saved many lives, they have inherent limitations, including late detection for certain aggressive cancers and the invasive nature of some procedures, as developed by Weihang [21]. The need for earlier detection, ideally before the appearance of macroscopic symptoms, for Dossouvi and Li [22], [23], has become an imperative to improve prognoses and reduce the morbidity associated with heavy treatments.

A. Early Cancer Detection: Challenges and Opportunities

Early cancer detection is crucial because it often allows for less aggressive treatments and significantly increases the chances of recovery as noted by Dhandapani and Cicatiello [24], [25]. However, many cancers, such as those of the pancreas, lung, or ovary, are often diagnosed at advanced stages due to the absence of specific symptoms or effective screening methods for the general population, as noted by Zafar [26]. Biomarkers, measurable biological indicators of a disease state, for Al Amin [27], offer a promising avenue for early detection. Research focuses on identifying blood, urine, or saliva biomarkers that could signal the presence of cancer at a very early stage, even before the formation of a tumor detectable by imaging like Noreen and Yu [28], [29]. Recent advances in liquid biopsies, for Dai [30], which analyze circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the blood, represent a major breakthrough in this field.

B. The Internet of Things (IoT) in Healthcare

The Internet of Things has revolutionized many sectors, and healthcare is no exception. IoT devices in healthcare, often as proposed by Meddaoui [31] referred to as the Internet of Medical Things (IoMT), are sensors, wearables, implants, or connected medical equipment that collect and transmit physiological data in real-time. For El-Saleh [32], these devices can monitor a multitude of parameters, such as heart rate, blood pressure, body temperature, physical activity, sleep, blood glucose, and even specific biomarkers via noninvasive or minimally invasive sensors, as noted by Mansouri and Jin [33], [34]. IoT applications in healthcare are vast and include remote patient monitoring, for Unanah [35]. Chronic disease management, assistance for the elderly, and improving hospital efficiency, as noted by Dong and Koontalay [36],[37], for cancer detection, IoT devices offer the possibility of continuous and passive monitoring, capturing longitudinal data that can reveal subtle changes in an individual's health status, long before a symptom becomes apparent. As stated by Shen [38], for example, smartwatches can detect heart rhythm abnormalities, sleep sensors can identify circadian cycle disturbances, and environmental sensors can monitor exposure to risk factors, as noted by Bladon [39], recent research by Fritz [40] even explores wearable devices capable of measuring tumor size under the skin or capturing circulating cancer cells.

C. Deep Learning in Oncology

Deep learning, a branch of artificial intelligence, has demonstrated exceptional capabilities in analyzing complex data as proposed by Wani [41], particularly in image recognition, natural language processing, and pattern detection, as cited by Ali [42] in oncology, deep learning is increasingly used for various applications, ranging from tumor diagnosis and classification to predicting treatment response and drug discovery, as proposed by Meddaoui [43]. Convolutional Neural Networks (CNNs) are particularly effective for analyzing medical images (X rays, MRIs, histopathology), as cited by Kuklin [45], enabling tumor lesion detection, segmentation, and classification with accuracy comparable to, or even superior to, that of human experts, as noted by Karthik [44]. Recurrent Neural Networks (RNNs) and their variants (LSTM, GRU) are suitable for analyzing sequential and temporal data, making them relevant for studying electronic medical records, continuous monitoring data, or genomic sequences, as noted by Kim and Abbasi [46] ,[47]. Autoencoders, on the other hand, are used for dimensionality reduction, anomaly detection, and data generation, crucial tasks for identifying weak signals in vast datasets, as mentioned by Armoogum [48]. In addition to these general advances, several recent studies have proposed specialized deep learning architectures for cancer prediction, as proposed by Gao [49], who introduced a transfer learning-based model for breast cancer classification, demonstrating how pre-trained networks can improve diagnostic accuracy in oncology. As cited by Vinoth [50], a segmentation and selection approach was developed for biomedical images, showing that fine-grained image analysis enhances tumor identification. Nobel [51] presented the ResECA-U-Net model, which improved organ segmentation for gastrointestinal cancer radiation therapy, thereby supporting more precise treatment planning. While these contributions confirm the growing impact of advanced

deep learning methods in oncology, they remain largely centered on imaging-based applications and reactive detection. In contrast, our work explicitly focuses on the integration of continuous multimodal IoT data with advanced hybrid deep learning models to enable proactive cancer prediction before the onset of symptoms.

This review of the literature underscores a critical research gap: although significant progress has been made in both IoT-driven healthcare and deep learning for oncology, no existing study has yet proposed, as said by Meddaoui [52], an integrated, end-to-end framework that combines multimodal IoT data acquisition with deep learning as architectures specifically tailored for proactive, pre-symptomatic cancer prediction. Addressing this gap constitutes the central focus of the methodology presented in the following section.

The convergence of these three areas, namely the need for early cancer detection, the ability of IoT to collect continuous and multidimensional data, as said by Eita [53], and the analytical power of deep learning, opens unprecedented perspectives for proactive cancer prediction, as cited by Eita [53]. By combining these technologies, it becomes possible to shift from a reactive approach to a truly preventive one, identifying individuals at risk long before the appearance of clinical symptoms.

III. Proposed Methodology: Proactive Cancer Prediction System

Our proposed methodology aims to establish a continuous monitoring and proactive cancer prediction system, leveraging the capabilities of the Internet of Things (IoT) for data collection and deep learning for predictive analysis. This system is designed to operate in the background, collecting subtle and multidimensional information about an individual's health, long before the appearance of overt clinical symptoms. The overall system architecture is illustrated in Fig. 1, which depicts the data flow from IoT devices to deep learning models and, ultimately, to the generation of risk predictions.

The system consists of three main modules: IoT data collection, data preprocessing and normalization, and deep learning architectures for pattern detection. Each module is crucial for the system's robustness and accuracy, ensuring that raw data is transformed into actionable information for cancer prediction.

A. Data Collection via IoT

The cornerstone of our approach lies in the continuous and non-invasive collection of high-resolution physiological and behavioral data. We envision the use of a diverse range of IoT devices, each designed to capture specific aspects of an individual's health. These devices can be classified into several categories:

Wearable Devices: Include smartwatches, fitness trackers, skin patches, and smart clothing. They are capable of measuring parameters such as heart rate, heart rate variability, body temperature, sleep patterns (sleep phases, interruptions), physical activity levels (step count, calories burned, exercise intensity), stress levels (via skin conductance or heart rate variability), and ambient light exposure. Some advanced devices can also monitor blood oxygen saturation (SpO2) and blood pressure, as cited by Asif [54]. Implantable Devices: Although more invasive, these devices offer superior precision and continuity of measurement for certain parameters. They may include subcutaneous glucose sensors, implantable cardiac monitors, and potentially, in the future, biosensors capable of detecting specific biomarkers in blood or interstitial fluids, as mentioned by Gurcan [55]. Environmental Sensors: Sensors integrated into the home or professional environment can collect data on air quality (pollutants, VOCs), temperature, humidity, noise levels, and UV exposure. This data is crucial because environmental factors play a significant role in cancer development for Fabbrocini [56]. Behavioral Monitoring Devices**:** Motion sensors, cameras (with strict privacy considerations), or mobile applications can record data on eating habits, movement patterns, social interactions, and exposure levels to certain environments. This information can reveal subtle changes in behavior that could be linked to underlying physiological alterations, as cited by Leadbeater [57]. Data collection is performed continuously and passively, minimizing interference with the user's daily life. The data is then securely transmitted via wireless communication protocols (Bluetooth Low Energy, Wi Fi, LoRaWAN, 5G) to a centralized cloud platform, as proposed by Locatelli [58], where it is stored and prepared for analysis. Data security and confidentiality are paramount concerns, requiring robust encryption protocols and strict compliance with data protection.



Fig. 1. Architecture of the proactive cancer prediction system.

B. Data Preprocessing and Normalization

Raw data collected by IoT devices are heterogeneous, as used by Wang [59], noisy, often incomplete, and come from diverse sources with different sampling frequencies and formats. Rigorous preprocessing is essential to transform this data into a clean, consistent format usable by deep learning models. This process includes several steps:

Data Cleaning: Identification and management of missing values, outliers, and measurement errors. Imputation techniques (mean, median, regression) can be used for missing data, while statistical or machine learning based methods can detect and correct outliers, as cited by Meddaoui [52]. Temporal Synchronization: Alignment of data streams from different sensors on a common time scale. This is crucial for analyzing correlations and dependencies between different physiological and behavioral parameters, as proposed by Reicher [60]. Normalization and Scaling: Transformation of data so that they have a similar value range and distribution. This is important to prevent certain attributes from dominating learning due to their larger scales. Methods such as min-max normalization or standardization (Z score) are commonly used by Desai [61]. Feature Engineering**:** Creation of new features from raw data that can better represent information relevant to cancer prediction. This may include descriptive statistics (mean, variance, min/max over time windows), frequency-based features (spectral analysis of physiological signals), or complexity indicators (entropy, fractals), as noted by Tobieha [62]. For proactive cancer detection, the focus is on micro changes and deviations from the individual's personalized baseline. This involves building individualized health profiles and monitoring significant deviations from these profiles over time, as mentioned by Asgari [63]. Dimensionality Reduction: When the number of features is very high, techniques such as Principal Component Analysis (PCA) or autoencoders can be used to reduce data dimensionality while preserving essential information. This reduces computational complexity and improves the performance of deep learning models.

C. Deep Learning Architectures for Pattern Detection

The core of our proactive prediction system lies in the use of advanced deep learning architectures, capable of processing complex, heterogeneous, and temporal data to identify subtle patterns and anomalies indicative of cancer risk. We propose a hybrid approach, combining several types of deep neural networks to leverage the different facets of the collected data.

1) Autoencoders for anomaly detection: Autoencoders (AEs) are unsupervised neural networks designed to learn a compressed representation (encoding) of input data, and then to reconstruct the original data from this representation. The idea is that the network learns the most important features of normal data. When abnormal data is presented to the autoencoder, the network will struggle to reconstruct it accurately, resulting in a high reconstruction error. This reconstruction error can serve as an anomaly indicator.

In our methodology, autoencoders will be trained on vast datasets of physiological and behavioral data collected from healthy individuals, thus establishing a personalized baseline of "normality" for each individual. Any significant deviation from this baseline, measured by an increase in reconstruction error, will be flagged as a potential anomaly. This approach is particularly useful for detecting subtle micro changes that do not correspond to known disease patterns but could indicate an early biological perturbation. We will explore different autoencoder architectures, including variational autoencoders (VAEs) for their ability to generate data and model the underlying data distribution, and deep autoencoders for their ability to capture complex representations.

2) Convolutional neural networks (CNNs) for multidimensional data: Convolutional Neural Networks (CNNs) are traditionally recognized for their excellence in processing image and video data, but their utility extends far beyond. In our context, CNNs will be employed to analyze multidimensional data collected by IoT devices, treating them as "images" or "grids" of data. For example, physiological data collected over a given period (heart rate, temperature, activity) can be organized into a matrix, where rows represent time and columns represent different parameters. Convolutional filters can then identify spatio temporal patterns in this data, such as correlations between different biomarkers or specific sequences of physiological changes CNNs are particularly well suited for extracting hierarchical and translation invariant features, meaning they can detect relevant patterns regardless of their position in the data stream. This is crucial for early cancer detection, where warning signs can be subtle and appear at unexpected times. We will consider 1D CNN architectures for time series, and potentially 2D or 3D if the data can be structured into more complex representations (e.g., heatmaps of biomarkers on the body or data volumes). The use of pooling layers will reduce dimensionality and make the model more robust to minor data variations.

3) Recurrent neural networks (RNNs) for time series data: Given the sequential and temporal nature of data collected by IoT devices, Recurrent Neural Networks (RNNs) are essential components of our methodology. RNNs, and particularly their variants such as Long Short-Term Memory (LSTM) and Gated Recurrent Units (GRU), are designed to process data sequences and capture long term dependencies within these sequences this fundamental to understanding the evolution of an individual's physiological and behavioral parameters over time.

For proactive cancer prediction, it is crucial not only to analyze data at a given moment but to understand trends, cycles, and deviations from the individual's usual patterns. RNNs can learn to model the temporal dynamics of health data, identifying, a gradual increase in resting heart rate over several weeks, or subtle changes in sleep patterns that could be early indicators of physiological stress or disease. By combining the outputs of autoencoders (reconstruction errors) and features extracted by CNNs, RNNs will be able to analyze these sequences of anomaly signals and patterns to predict cancer risk. The integration of attention mechanisms could also be explored to allow the model to focus on the most relevant segments of the time series for prediction.

The overall architecture of the deep learning model will be a combination of these approaches. Raw IoT data will first be

preprocessed. Then, autoencoders will detect anomalies relative to the individual baseline. Simultaneously, CNNs will extract relevant features from multidimensional data. Finally, RNNs will analyze the sequences of these features and anomalies to predict cancer risk. This hybrid model will leverage the strengths of each architecture for early and accurate detection of pre-symptomatic cancer signals.

IV. Experiments and Results

To validate the effectiveness of our proactive cancer prediction methodology, we conducted a series of experiments based on data simulations and case studies. The primary objective was to demonstrate the system's ability to detect pre-symptomatic cancer signals using continuous physiological and behavioral data, and to differentiate at-risk individuals from healthy individuals long before the onset of clinical symptoms. Given the ethical and practical constraints related to collecting real data on pre-symptomatic cancer development, our experiments were designed to simulate realistic scenarios based on existing scientific literature and disease progression models.

A. Experimental Design

Our experimental design revolved around the creation of a synthetic dataset representative of high-resolution IoT data streams, integrating subtle biomarkers and micro changes associated with early cancer development. We modeled three types of cancers for our case studies: pancreatic cancer, lung cancer, and ovarian cancer, chosen for their difficulty in early detection and their often grim prognosis at advanced stages. For each cancer type, we defined a set of key physiological and behavioral biomarkers known to be affected, even minimally, at pre-symptomatic stages.

The synthetic dataset was generated to simulate health profiles over a 12-month period, for a group of 1000 individuals, 200 of whom were designated as developing cancer during this period (the "case" group) and 800 as healthy individuals (the "control" group). For the "case" group, we introduced progressive micro changes in the relevant biomarker data, simulating the pre-symptomatic evolution of the disease. These changes were initially very subtle, becoming more pronounced as the simulated date of symptom onset approached.

Simulated parameters included:

- Resting Heart Rate (RHR**)**: Slight and progressive increase.
- Heart Rate Variability (HRV): Progressive decrease in HRV.
- Body Temperature: Subtle fluctuations or slight elevation.

1) Sleep quality: Decrease in sleep efficiency, increase in nocturnal awakenings. Physical Activity Levels: Progressive decrease in activity or changes in activity patterns.

2) Specific biomarkers (simulated): For each cancer, specific markers were modeled with progressive increases or decreases (e.g., for pancreatic cancer, changes in glucose levels or digestive enzymes; for lung cancer, micro changes in respiratory patterns; for ovarian cancer, hormonal alterations or inflammatory markers). The data was generated with an hourly sampling frequency for physiological parameters and daily for behavioral parameters, reflecting the capability of IoT devices. Random noise was added to simulate natural variability and measurement errors.

The parameters retained for the simulations, resting heart rate, heart rate variability, body temperature, sleep quality, physical activity, and cancer-specific biomarkers, were not chosen at random. Each of them is regularly cited in the medical literature as an early signal of systemic imbalance, metabolic disturbance, or inflammation linked to tumor development. We initially considered a broader set of indicators, but preliminary trials showed that this selection offered the best compromise between predictive value and the practical feasibility of measurement with IoT devices. A detailed sensitivity analysis remains a perspective for future work, but first checks already suggest that moderate changes in the parameter set do not fundamentally affect the predictive trends, which reinforces the robustness of the proposed system.

B. Datasets and Simulation

Because it is practically impossible and ethically complex to collect real longitudinal data on individuals before the onset of cancer symptoms, we opted for simulated datasets. These datasets were constructed on the basis of biomedical knowledge and published progression models, so that they reproduce, as realistically as possible, the small physiological and behavioral variations that may precede the appearance of the disease. Although simulations cannot replace clinical trials, they provide a controlled and reproducible framework that allows us to validate the feasibility of our approach and prepare the ground for future studies on real patient data.

The synthetic dataset was divided into a training set (80% of the data) and a test set (20% of the data). The training set was used to calibrate the autoencoders on normal health profiles and to train the CNN and RNN models to recognize micro change patterns associated with cancer risk. The test set was used to evaluate the system's performance on unseen data.

The simulation was performed in Python, using libraries such as NumPy for numerical data generation, Pandas for time series manipulation, and Scikit learn for noise generation and dataset splitting. Progression curve generation functions were implemented to simulate the evolution of biomarkers in the "case" group. The parameters of these curves (starting point of changes, slope, etc.) were adjusted to reflect the subtlety of pre-symptomatic alterations.

C. Performance Evaluation

The performance of our proactive prediction system was evaluated using several key metrics, adapted to the imbalanced nature of the data (many more healthy individuals than individuals developing cancer) and the objective of early detection. The main metrics include:

1) Accuracy: Proportion of correct predictions (true positives and true negatives) out of the total number of predictions.

2) Sensitivity (Recall): The model's ability to correctly identify all individuals who will develop cancer [true positives

/ (true positives + false negatives)]. This metric is crucial for early detection, as a false negative can have serious consequences.

3) Specificity: The model's ability to correctly identify healthy individuals [true negatives / (true negatives + false positives)].

4) Positive predictive value (PPV): Proportion of true positives among all positive predictions [true positives / (true positives + false positives)].

5) Area under the ROC curve (AUC ROC): Overall measure of classifier performance, independent of the classification threshold. A high AUC ROC indicates a good ability to distinguish between classes.

6) Early detection lead time: The average time (in months) between the system's prediction and the simulated onset of clinical symptoms. This is a specific metric for our proactive prediction objective.

Deep learning models (autoencoders, CNN, RNN) were trained on the entire training dataset. Autoencoders were used to generate an anomaly score for each individual over time. These scores, combined with features extracted by CNNs, were fed into RNNs to predict cancer risk. A risk threshold was defined to classify an individual as being at high risk of developing cancer.

Results showed that the system was able to detect pre-symptomatic signals with high sensitivity and a significant early detection lead time.



Fig. 2. Average ROC curve of the prediction model on the test set.

Fig. 2 illustrates the average ROC curve obtained on the test set, demonstrating the model's robustness.

TABLE I SUMMARY OF OVERALL PERFORMANCE OF THE PROACTIVE CANCER PREDICTION SYSTEM

Metric	Value
Accuracy	89%
Sensitivity	85%
Specificity	91%
PPV	87%
AUC ROC	0.93
Average Early Detection Lead Time	7.5 months

This table summarizes the key performance metrics of the system on the test set, such as accuracy, sensitivity, specificity, positive predictive value, AUC ROC, and average early detection lead time. Table I summarizes the system's overall performance.

These findings go beyond reporting standard accuracy measures. They show that the proposed system does not simply classify patients correctly but also anticipates the onset of disease by several months. The introduction of the "early detection lead time" as an evaluation metric underlines the proactive nature of the framework. On average, the system identified individuals at risk 7.5 months before the simulated appearance of symptoms. This element is crucial because it translates predictive performance into a clinically meaningful advantage, and it clearly separates our work from existing approaches that are still reactive or symptom-driven.

D. Comparison and Detailed Metrics

To evaluate the robustness and performance of our hybrid approach (Autoencoders + CNN + RNN), we conducted a comparative study with other deep learning architectures commonly used for time series analysis and classification. The compared algorithms include a model based solely on CNNs, a model based solely on RNNs (LSTM), and a traditional Machine Learning model (e.g., Support Vector Machine, SVM or Random Forest) applied to extracted features. The objective was to demonstrate the superiority of our integrated Methodology for early cancer detection.

The evaluation metrics used for this comparison are Average Precision, Average Recall, Average F1 score, and Accuracy. These metrics are particularly relevant for imbalanced classification problems, where the positive class (cancer) is a minority.

TABLE II COMPARATIVE PERFORMANCE OF DIFFERENT ALGORITHMS

Algorithm	Average Precision	Average Recall	Average F1 score
Our Hybrid Model (AE+CNN+RNN)	0.90	0.88	0.89
CNN Only	0.82	0.75	0.78
RNN (LSTM) Only	0.80	0.72	0.76
SVM	0.70	0.65	0.67
Random Forest	0.72	0.68	0.70

Table II presents the comparative performance of the different algorithms on the test set. It is clear that our hybrid approach outperforms individual and traditional models on most metrics, especially sensitivity and F1 score, which is crucial for minimizing false negatives in cancer detection.

1) Confusion matrix: The confusion matrix provides a detailed view of classifier performance by showing the number of true positives (TP), true negatives (TN), false positives (FP), and false negatives (FN). For our hybrid model, the average confusion matrix on the test set is presented in Fig. 3.

The results show a low number of false negatives, which is essential for a proactive cancer prediction system, as a false negative could delay a vital diagnosis.

- True Positives (TP): Correctly identified cancer cases.

- True Negatives (TN): Correctly identified non-cancer cases.
- False Positives (FP): Non-cancer cases mistakenly identified as cancer (can lead to unnecessary stress and additional examinations).
- False Negatives (FN): Cancer cases mistakenly identified as non-cancer (the most critical, as it delays diagnosis and treatment).



Fig. 3. Average confusion matrix of the hybrid model.

The low false negative rate, combined with an acceptable false positive rate, confirms our model's ability to reliably identify at-risk individuals while minimizing unnecessary alerts.

E. Model Training Analysis

Training deep learning models is an iterative process, where network weights are adjusted to minimize a loss function and maximize accuracy on training data. For our hybrid model (Autoencoders + CNN + RNN), we closely monitored training loss and training accuracy over epochs. These metrics are crucial for understanding model behavior during learning and for detecting issues such as overfitting or underfitting.



Fig. 4. Training loss and validation loss curves.

Fig. 4 illustrates the training loss and validation loss curves during training. Ideally, both curves should decrease steadily and stabilize at low values, indicating that the model learns effectively and generalizes well to unseen data. A significant divergence between training loss and validation loss could indicate overfitting, where the model memorizes training data rather than learning generalizable patterns.



Fig. 5. Training accuracy and validation accuracy curves.

Fig. 5 presents the training accuracy and validation accuracy curves. A gradual increase in accuracy on both datasets is desirable. The convergence of both curves towards high values indicates a well-trained model capable of making accurate predictions on new data.

The learning rate was adaptively adjusted to optimize model convergence. We used a learning rate decay strategy to allow for finer adjustments of model weights as training progresses. The number of epochs was determined by an early stopping strategy based on performance on the validation set, to prevent overfitting and find the optimal point, where the model generalizes best.

These analyses of training curves confirm the stability and effectiveness of our hybrid model's learning process, reinforcing confidence in its predictive capabilities.

F. Case Studies: Pancreatic, Lung, and Ovarian Cancers

We applied our methodology to three specific case studies to evaluate its performance in the proactive prediction of distinct cancers, each presenting unique challenges in early detection.

1) Pancreatic cancer: Pancreatic cancer is one of the most lethal cancers, primarily due to its late diagnosis. Our simulations introduced micro changes in parameters such as blood glucose, digestive enzymes (amylase, lipase), and metabolic stress indicators. The system showed promising ability to identify at risk individuals an average of six to eight months before the simulated onset of symptoms. Autoencoders were particularly effective in detecting subtle anomalies in metabolic profiles, while RNNs identified progressive trends in these anomalies. Sensitivity for pancreatic cancer detection was 85%, with a specificity of 92%.

2) Lung cancer: Lung cancer is often diagnosed at an advanced stage, despite screening programs for high-risk populations. For this case study, we simulated changes in respiratory patterns (frequency, tidal volume), oxygen saturation, heart rate, and inflammation indicators. Our model was able to predict lung cancer risk an average of 4 to 6 months before symptom onset. CNNs played a key role in identifying complex patterns in respiratory data, and RNNs tracked the evolution of these patterns. Performance reached a sensitivity of 88% and a specificity of 90%.

3) Ovarian cancer: Ovarian cancer is notoriously difficult to detect early due to non-specific symptoms. Our simulations focused on hormonal biomarkers, inflammation indicators, changes in sleep patterns, and activity levels. The system demonstrated an ability to predict ovarian cancer risk an average of seven to nine months before symptom onset. Autoencoders were essential for spotting subtle deviations in hormonal and inflammatory profiles. Sensitivity was 82% and specificity was 91%.

These case studies demonstrate the versatility of our Methodology and its ability to adapt to different cancer types by identifying disease-specific pre-symptomatic signals. The results highlight the potential of integrating IoT and deep learning to transform cancer detection into a proactive and preventive approach.

V. Discussion

The proactive cancer prediction Methodology we proposed, integrating the Internet of Things (IoT) and deep learning, represents a significant advance in the quest for ultra-early disease detection. The results of our simulations and case studies, although based on synthetic data, demonstrate the potential of this approach to radically transform the landscape of oncology, moving from a reactive model to a truly preventive one.

A. Clinical Implications and Benefits

The main clinical implication of our system is the possibility of identifying individuals at high risk of developing cancer long before the onset of clinical symptoms. This window of opportunity, which can extend over several months or even years, offers considerable advantages:

1) Early and personalized intervention: Pre-symptomatic detection would allow clinicians to intervene at a stage where the disease is potentially easier to treat, or even prevent its progression. This could include lifestyle modifications, targeted pharmacological interventions, or more intensive and personalized clinical monitoring. For example, for an individual identified at risk of lung cancer, reinforced smoking cessation advice or more frequent low dose imaging examinations could be implemented.

2) Improved survival rates: For cancers such as pancreatic, lung, and ovarian, where diagnosis is often late and prognosis grim, early detection means a drastic increase in survival rates. By identifying the disease at its earliest stages, treatments could be less invasive and more effective, thereby reducing morbidity and improving patients' quality of life.

3) Reduced healthcare costs: Although the initial investment in IoT infrastructure and AI systems can be significant, cancer prevention and early treatment could ultimately significantly reduce healthcare costs associated with advanced treatments, prolonged hospitalizations, and palliative care.

4) Personalized and predictive medicine: Our methodology fully aligns with the era of personalized medicine. By establishing an individual baseline for each patient and detecting deviations from this norm, the system allows for a highly individualized approach to risk management. Predictions are not based on population averages, but on the unique changes observed in the individual.

5) Passive and non-invasive data collection: The use of IoT devices allows for continuous and passive data collection, minimizing the burden on the patient and maximizing the amount of information gathered. Unlike sporadic clinical visits, this constant monitoring offers a holistic and dynamic view of health status.

Beyond these clinical benefits, the results must also be considered in relation to the broader research landscape. As underlined in the literature review, most existing studies rely on a single data modality, such as imaging or genomics, and therefore remain largely reactive. By contrast, our framework demonstrates that heterogeneous IoT signals covering physiological, behavioral, and environmental dimensions can be continuously collected and analyzed through a hybrid combination of autoencoders, CNNs, and RNNs. This not only extends the technical possibilities of deep learning in oncology but also represents a conceptual advance. It shows that multimodal and longitudinal monitoring can provide actionable early warnings months before clinical manifestation. This ability to operationalize the proactive paradigm highlights both the novelty and the added value of our contribution to predictive oncology. Taken together, the results provide a clear answer to the research questions posed at the beginning of this study. First, they show that continuous IoT-based monitoring can indeed capture subtle physiological and behavioral changes that precede the clinical onset of cancer. Second, they confirm that a hybrid deep learning architecture, combining autoencoders, CNNs, and RNNs, is capable of transforming these weak signals into reliable early risk predictions. By validating both of these assumptions, the study confirms that the proposed methodology directly addresses the identified research gap and fulfills the central objective of enabling proactive, pre-symptomatic cancer prediction.

B. Challenges and Limitations

Despite the promises of our approach, several challenges and limitations must be addressed for successful real-world implementation:

1) Quality and volume of real data: Our experiments are based on synthetic data. The collection of real, longitudinal, high-resolution data on large cohorts of individuals developing pre-symptomatic cancer is a major challenge. This requires

large-scale prospective studies, robust data collection infrastructures, and rigorous ethical considerations. Inter-individual and intra-individual variability of biomarkers also makes the task complex.

2) Data privacy and security: The continuous collection of sensitive health data raises important privacy and security concerns. End-to-end encryption protocols, secure storage architectures, and strict compliance with regulations (GDPR, HIPAA) are imperative. User trust is essential for the adoption of such systems.

3) False positives and false negatives: Although our simulations show good performance, the presence of false positives (individuals identified at risk but not developing cancer) and false negatives (individuals developing cancer but not detected by the system) remains a concern. False positives can lead to unnecessary stress, costly and invasive additional examinations. False negatives, on the other hand, can give false assurance and delay a necessary diagnosis. Optimizing detection thresholds and integrating multiple data sources for validation are crucial.

4) Interpretability of deep learning models: Deep learning models, especially deep networks, are often considered "black boxes", making it difficult to understand why a specific prediction was made. In the medical field, where trust and justification are paramount, model interpretability is essential. Explainable AI (XAI) techniques will need to be integrated to provide clear explanations of the factors that led to a risk prediction, allowing clinicians to make informed decisions and patients to understand their situation. Clinical Validation and Regulation: Before such a system can be deployed on a large scale, rigorous clinical validation on large cohorts of real patients is essential. This will require prospective clinical trials to confirm the accuracy, reliability, and clinical utility of the system. Furthermore, regulatory Methodologies will need to evolve to govern the development and use of these AI and IoT-based health technologies, ensuring their safety and effectiveness. Acceptance by Users and Healthcare Professionals: The adoption of this type of technology will also depend on its acceptance by patients and healthcare professionals. Patients will need to be comfortable with continuous monitoring and sharing of their data, while healthcare professionals will need to be trained to interpret results and integrate this new information into their clinical practice. Ease of use, reliability, and perceived added value will be key adoption factors.

Despite these challenges, the transformative potential of proactive cancer prediction fully justifies research and development efforts. Continuous advances in IoT sensors, deep learning algorithms, and data infrastructures promise to gradually overcome these obstacles, paving the way for a new era of preventive medicine.

VI. Conclusion and Future Perspectives

This study addressed the research gap identified in the literature by proposing an end-to-end framework for proactive cancer prediction that integrates continuous multimodal IoT monitoring with hybrid deep learning models. Unlike most existing works, which remain reactive and focus mainly on imaging-based detection, our approach targets the pre-symptomatic phase, aiming to anticipate disease onset before clinical manifestation. The contributions of this work are threefold. First, it demonstrates the feasibility of combining heterogeneous IoT signals with autoencoders, CNNs, and RNNs to capture subtle physiological and behavioral changes preceding cancer symptoms. Second, it introduces the "early detection lead time" as a new evaluation metric, showing that the framework can identify individuals at risk on average 7.5 months earlier than conventional detection. Third, the methodology was validated across three cancer types: pancreatic, lung, and ovarian, highlighting its generalizability. Together, these contributions provide a concrete answer to the research questions posed in the introduction: continuous IoT monitoring can indeed detect early deviations, and hybrid deep learning can reliably translate them into actionable predictions. While promising, the work also faces challenges. The use of simulated datasets underscores the need for real longitudinal data capturing the pre-symptomatic phase of cancer progression. Data privacy, model interpretability, and rigorous clinical validation within appropriate regulatory frameworks remain critical issues. Future research should therefore focus on several directions: integrating multi-omics data to enrich predictive capacity; advancing IoT sensors to capture more diverse biomarkers in a non-invasive manner; applying federated learning to ensure privacy; developing explainable AI techniques to increase trust and adoption; and, most importantly, conducting large-scale prospective clinical trials to validate effectiveness in real-world settings. By addressing these challenges, the proposed framework has the potential to transform oncology from a reactive discipline into a preventive one. Detecting cancer at its earliest stage not only improves survival prospects and reduces treatment burden but also redefines the role of healthcare from responding to disease to preventing it before harm occurs.

References

[1] Hussain, sadam, ali, mansoor, naseem, usman, *et al.* Breast cancer risk prediction using machine learning: a systematic review. *Frontiers in oncology*, 2024, vol. 14, p. 1343627.

[2] Moglia, victoria, johnson, owen, cook, gordon, *et al.* Artificial intelligence methods applied to longitudinal data from electronic health records for prediction of cancer: a scoping review. *Bmc medical research methodology*, 2025, vol. 25, no 1, p. 24.

[3] Gong, xiaoling, ye, zheng, shen, yu, et al. Enhancing the role of mri in rectal cancer: advances from staging to prognosis prediction. European radiology, 2025, p. 1-19.

[4] Ye, bicheng, fan, jun, xue, lei, et al. Imlgam: integrated machine learning and genetic algorithm - driven multiomics analysis for pan - cancer immunotherapy response prediction. Imeta, 2025, vol. 4, no 2, p. E70011.

[5] Panda, pinakshi, bisoy, sukant kishoro, panigrahi, amrutanshu, et al. Bimssa: enhancing cancer prediction with salp swarm optimization and ensemble machine learning approaches. Frontiers in genetics, 2025, vol. 15, p. 1491602.

[6] Tirumanadham, ns koti mani kumar, priyadarshini, v., praveen, s. Phani, et al. Optimizing lung cancer prediction models: a hybrid methodology using gwo and random forest. In : enabling person-centric healthcare using ambient assistive technology, volume 2: personalized and patient-centric healthcare services in aat. Cham : springer nature switzerland, 2025. P. 59-77.

[7] Yang, zhaochang, wei, ting, liang, ying, et al. A foundation model for generalizable cancer diagnosis and survival prediction from histopathological images. Nature communications, 2025, vol. 16, no 1, p. 2366.

[8] Meddaoui, mohamed amine et erritali, mohammed. Smart irrigation integrate to iot technology based on deep learning's algorithm lstm. In : 2024 mediterranean smart cities conference (mscc). Ieee, 2024. P. 1-5.

[9] Anandan, heber, et al. Tumor growth stage prediction on ultrasound breast cancer images with backpropagation network. Grn int j apl med sci, 2025, vol. 3, no 3, p. 118-121.

[10] Zhang, ziye, huang, weixian, wang, shijin, et al. Adfusion: multi-modal adaptive deep fusion for cancer subtype prediction. Information fusion, 2025, vol. 121, p. 103138.

[11] Youssef, doaa, atef, hanan, gamal, shaimaa, et al. Early breast cancer prediction using thermal images and hybrid feature extraction based system. Ieee access, 2025.

[12] Zaher, moamen, ghoneim, amr s., abdelhamid, laila, et al. Unlocking the potential of rnn and cnn models for accurate rehabilitation exercise classification on multi-datasets. Multimedia tools and applications, 2025, vol. 84, no 3, p. 1261-1301.

[13] Savka, maksym. Analysis of the key models, methods, and means of data collection in the internet of things. Technologies and engineering, 2025, vol. 26, no 2, p. 66-78.

[14] Mukherjee, sovanlal, antony, ajith, patnam, nandakumar g., et al. Pancreas segmentation using ai developed on the largest ct dataset with multi-institutional validation and implications for early cancer detection. Scientific reports, 2025, vol. 15, no 1, p. 17096.

[15] Islam, md ariful, mahmud, mohammad rasel, sakib, anamul haque, et al. Time domain feature analysis for gas pipeline fault detection using lstm. International journal of science and research archive [internet], 2025, p. 1769-77.

[16] Alatawi, mohammed naif. Optimizing security and energy efficiency in iot-based health monitoring systems for wireless body area networks. Scientific reports, 2025, vol. 15, no 1, p. 24921.

[17] Parra, milena, prada, andrea, casallas, alexander, et al. Proposals for the implementation of a multidimensional platform that allows the advancement of oncology nursing in the latin american environment (the increase proposal). Jco global oncology, 2025, vol. 11, p. E2400183.

[18] Soto, claudio, mollenhauer, brit, hansson, oskar, et al. Toward a biological definition of neuronal and glial synucleinopathies. Nature medicine, 2025, vol. 31, no 2, p. 396-408.

[19] Mangayarkarasi, v., durairaj, elantamilan, ramanathan, vijaya, et al. Enhancing cancer screening and early diagnosis in india: overcoming challenges and leveraging emerging technologies. Cureus, 2025, vol. 17, no 2.

[20] Meddaoui, mohamed amine. Semantic web for sharing medical resources. In : international conference on business intelligence. Cham : springer international publishing, 2021. P. 388-398.

[21] Su, weihang, tang, yichen, ai, qingyao, et al. Parametric retrieval augmented generation. In : proceedings of the 48th international acm sigir conference on research and development in information retrieval. 2025. P. 1240-1250.

[22] Dossouvi, komla mawunyo, sellera, fábio parra, ibadin, ephraim ehidiamen, et al. Recommendations and adjuvant therapies to mitigate clarithromycin-resistant helicobacter pylori-associated infections in africa. Infection and drug resistance, 2025, p. 3169-3174.

[23] Li, shuiquan, chen, xi, shi, hui, et al. Tailoring traditional chinese medicine in cancer therapy. Molecular cancer, 2025, vol. 24, no 1, p. 27.

[24] Dhandapani, gokila, n, porchelvi, u, arun kumar, et al. Design and development of graphene-based c-shaped silicon-mgf2-silicon materials surface plasmon resonance biosensor for cervical cancer detection. Plasmonics, 2025, p. 1-11.

[25] Cicatiello, annunziata gaetana, musone, michele, imperatore, silvestro, et al. Circulating mirnas in genitourinary cancer: pioneering advances in early detection and diagnosis. The journal of liquid biopsy, 2025, vol. 8, p. 100296.

[26] Zafar, aasma, khatoon, summaiya, khan, muhammad jawad, et al. Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy. Discover oncology, 2025, vol. 16, no 1, p. 607.

[27] Al amin, md, liza, irin akter, hossain, shah foysal, et al. Enhancing patient outcomes with ai: early detection of esophageal cancer in the usa. Journal of medical and health studies, 2025, vol. 6, no 1, p. 08-27.

[28] Noreen, sana, ishaq, izwa, saleem, muhammad hamzah, et al. Electrochemical biosensing in oncology: a review advancements and prospects for cancer diagnosis. Cancer biology & therapy, 2025, vol. 26, no 1, p. 2475581.

[29] Yu, hai-jia, liu, jian-hua, liu, wei, et al. Metal-based nanomedicines for cancer theranostics. Military medical research, 2025, vol. 12, no 1, p. 41.

[30] Dai, charles s., mishra, avanish, edd, jon, et al. Circulating tumor cells: blood-based detection, molecular biology, and clinical applications. Cancer cell, 2025.

[31] Meddaoui, mohamed amine, erritali, mohammed, et al. A comparative study of embedded learning models iot-based for real time mask detection. International journal of advanced science and computer applications, 2024, vol. 3, no 2.

[32] El-saleh, ayman a., sheikh, abdul manan, albreem, mahmoud am, et al. The internet of medical things (iomt): opportunities and challenges. Wireless networks, 2025, vol. 31, no 1, p. 327-344.

[33] Mansouri, wahida, alohali, manal abdullah, alqahtani, hamed, et al. Deep convolutional neural network-based enhanced crowd density monitoring for intelligent urban planning on smart cities. Scientific reports, 2025, vol. 15, no 1, p. 5759.

[34] Jin, yuebo et huang, yadong. Long-term vital sign tracking study of depression patients based on wearable devices. International journal of crowd science, 2025, vol. 9, no 1, p. 56-63.

[35] Unanah, onyekachukwu victor et aidoo, esi mansa. The potential of ai technologies to address and reduce disparities within the healthcare system by enabling more personalized and efficient patient engagement and care management. World journal of advanced research and reviews, 2025, vol. 25, no 2, p. 2643-64.

[36] Dong, chaoqun, ji, yan, fu, zhongmin, et al. Precision management in chronic disease: an ai empowered perspective on medicine-engineering crossover. Iscience, 2025, vol. 28, no 3.

[37] Koontalay, apinya, botti, mari, et hutchinson, anastasia. Development of a user - centred chronic care model for patients with heart failure in a limited - resource setting: a codesign study. Health expectations, 2025, vol. 28, no 1, p. E70142.

[38] Shen, shiying, qi, wenhao, zeng, jianwen, et al. Passive sensing for mental health monitoring using machine learning with wearables and smartphones: scoping review. Journal of medical internet research, 2025, vol. 27, p. E77066.

[39] Bladon, siân, eisner, emily, bucci, sandra, et al. A systematic review of passive data for remote monitoring in psychosis and schizophrenia. Npj digital medicine, 2025, vol. 8, no 1, p. 62.

[40] Fritz, roschelle, cook, diane, et al. Detecting older adults' behavior changes during adverse external events using ambient sensing: longitudinal observational study. Jmir nursing, 2025, vol. 8, no 1, p. E69052.

[41] Wani, m. Arif, ali, sarwat, sofi, mukhtar ahmad, et al. Advances in deep learning, volume 2. Springer nature, 2025.

[42] Ali, muhammad, benfante, viviana, basirinia, ghazal, et al. Applications of artificial intelligence, deep learning, and machine learning to support the analysis of microscopic images of cells and tissues. Journal of imaging, 2025, vol. 11, no 2, p. 59.

[43] Meddaoui, mohamed amine, amzil, moulay, karkaba, imane, et al. Deep learning optimization conception: less data, less time, more performance. International journal of advanced computer science & applications, 2025, vol. 16, no 7.

[44] Karthik, a., sahoo, santosh kumar, kumar, ajay, et al. Unified approach for accurate brain tumor multi-classification and segmentation through fusion of advanced methodologies. Biomedical signal processing and control, 2025, vol. 100, p. 106872.

[45] V. Z. Kuklin, l. M. Chervyakov, a. N. Ruslantsev, and t. G. Aslanov, "technique for segmentation and selection of biomedical images", j. Hum. Earth future, vol. 5, no. 4, pp. 688–703, dec. 2024

[46] Kim, dong won, seo, jihoon, kwon, sujin, et al. Predicting in - hospital fall risk using machine learning with real - time location system and electronic medical records. Journal of cachexia, sarcopenia and muscle, 2025, vol. 16, no 1, p. E13713.

[47] Abbasi, fereshteh, naderan, marjan, et alavi, seyed enayatallah. Dimensionality reduction with deep learning classification for botnet detection in the internet of things. Expert systems with applications, 2025, vol. 267, p. 126149.

[48] S. Armoogum, k. Motean, d. A. Dewi, t. B. Kurniawan, and j. Kijsomporn, "breast cancer prediction using transfer learning-based classification model", emerg sci j, vol. 8, no. 6, pp. 2373–2384, dec. 2024.

[49] Gao, ding, zhi, yuan, rong, xing, et al. Mismatch analysis of rooftop photovoltaics supply and farmhouse load: data dimensionality reduction and explicable load pattern mining via hybrid deep learning. Applied energy, 2025, vol. 377, p. 124520.

[50] Vinoth, n. A. S., kalaivani, j., arieth, r. Madonna, et al. An enhanced fusion of transfer learning models with optimization based clinical diagnosis of lung and colon cancer using biomedical imaging. Scientific reports, 2025, vol. 15, no 1, p. 24247.

[51] S. M. N. Nobel, o. F. Sifat, m. R. Islam, m. S. Sayeed, and m. Amiruzzaman, "enhancing gi cancer radiation therapy: advanced organ segmentation with reseca-u-net model", emerg sci j, vol. 8, no. 3, pp. 999–1015, jun. 2024.

[52] Meddaoui, mohamed amine, erritali, mohammed, madani, youness, et al. Mask detection using iot-a comparative study of various learning models. In : international conference on smart homes and health telematics. Cham : springer international publishing, 2022. P. 272-283.

[53] Eita, mohammad a. Et rizk, hamada. A trustworthy and explainable deep learning framework for skin lesion detection in smart dermatology. Engineering applications of artificial intelligence, 2025, vol. 159, p. 111594.

[54] Asif, sohaib, wenhui, yi, ur-rehman, saif-, et al. Advancements and prospects of machine learning in medical diagnostics: unveiling the future of diagnostic precision. Archives of computational methods in engineering, 2025, vol. 32, no 2, p. 853-883.

[55] Gurcan, fatih. Enhancing breast cancer prediction through stacking ensemble and deep learning integration. Peerj computer science, 2025, vol. 11, p. E2461.

[56] Fabbrocini, gabriella, triassi, maria, mauriello, maria chiara, et al. Epidemiology of skin cancer: role of some environmental factors. Cancers, 2010, vol. 2, no 4, p. 1980-1989.

[57] Leadbeater, ellouise et watrobska, cecylia. What could evolve in the evolution of memory?. Philosophical transactions b, 2025, vol. 380, no 1929, p. 20240109.

[58] Locatelli, pierluigi, et al. Investigating secure and distributed control in iot: improving ble security and strengthening lorawan with blockchain. 2025.

[59] Wang, jing, quasim, mohammad tabrez, et yi, bo. Privacy-preserving heterogeneous multi-modal sensor data fusion via federated learning for smart healthcare. Information fusion, 2025, vol. 120, p. 103084.

[60] Reicher, lee, shilo, smadar, godneva, anastasia, et al. Deep phenotyping of health–disease continuum in the human phenotype project. Nature medicine, 2025, p. 1-13.

[61] Desai, priyanka, karthik, p., loganathan, d., et al. Different data cleaning techniques and normalization techniques with focus on current normalization techniques: a study. In : advances in electrical and computer technologies. Crc press, 2025. P. 332-349.

[62] Tobieha, atefeh, behzadfar, neda, yousefi, mohammadreza, et al. Analysing and investigating the effect of heroin use disorder for the changes of distinguishing features in brain signal processing. Iet science, measurement & technology, 2025, vol. 19, no 1, p. E70023.

[63] Asgari mehrabadi, milad, khatibi, elahe, jimah, tamara, et al. Perfect: personalized exercise recommendation framework and architecture. Acm transactions on computing for healthcare, 2025, vol. 5, no 4, p. 1-25.